6533b7dcfe1ef96bd1272a1c

RESEARCH PRODUCT

Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index

Maurice MichelChristoph DüberDaniel Pinto Dos SantosSimon Johannes GairingAline Mähringer-kunzMichael B. PittonFriedrich FoersterFelix HahnFabian StoehrJens MittlerRoman KloecknerLukas MüllerPeter R. GalleArndt Weinmann

subject

Cancer Researchmedicine.medical_specialtyMultivariate statisticsIndex (economics)Scoring systemFuture studiesMultivariate analysistransarterial chemoembolizationGastroenterologyArticlerisk predictionInternal medicinemedicineOverall survivalRC254-282inflammation indexbusiness.industryfungiUnivariateNeoplasms. Tumors. Oncology. Including cancer and carcinogenshepatocellular carcinomamedicine.diseaseCRP–albumin–lymphocyte ratioimmunoscoringOncologyHepatocellular carcinomabusiness

description

The novel CRP–albumin–lymphocyte (CALLY) index is an improved immunonutritive scoring system, based on serum C-reactive protein (CRP), serum albumin, and the lymphocyte count. It has shown promise as a prognostic index for patients with hepatocellular carcinoma (HCC) undergoing resections. This study evaluated the prognostic ability of the CALLY index for patients with HCC undergoing transarterial chemoembolization (TACE). We retrospectively identified 280 treatment-naïve patients with HCC that underwent an initial TACE at our institution, between 2010 and 2020. We compared the CALLY index to established risk factors in univariate and multivariate regression analyses for associations with median overall survival (OS). A low CALLY score was associated with low median OS (low vs. high CALLY: 9.0 vs. 24.0 months, p &lt

yearjournalcountryeditionlanguage
2021-10-01Cancers
10.3390/cancers13195018http://europepmc.org/articles/PMC8508385